| 1. |
Carosi G et al. Treatment of chronic hepatitis B: update of the recommendations from the 2007 Italian Workshop. Dig Liver Dis. 2011;43(4):259-65. |
| |
| 2. |
European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B. J Hepatol 2009;50(2):227-242. |
| |
| 3. |
Buster EH et al. Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa. Gastroenterology. 2009;137(6):2002-9. |
| |
| 4. |
Marcellin P et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med. 2008;359(23):2442-55. |
| |
| 5. |
Tenney DJ et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy. Hepatology. 2009;49(5):1503-14. |
| |
| 6. |
Lampertico P. Partial virological response to nucleos(t)ide analogues in naïve patients with chronic hepatitis B: From guidelines to field practice. J Hepatol. 2009;50(4):644-7. |
| |
| 7. |
Woo G et al. Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and Bayesian meta-analyses. Gastroenterology. 2010;139(4):1218-29. |
| |
| 8. |
Liaw YF et al. Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease. Hepatology. 2011;53(1):62-72. |
| |
| 9. |
Garg H et al. Tenofovir improves the outcome in patients with spontaneous reactivation of hepatitis B presenting as acute-on-chronic liver failure. Hepatology. 2011;53(3):774-80. |
| |
| 10. |
Heathcote EJ et al. Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Gastroenterology. 2011;140(1):132-43. |
| |
| 11. |
Lampertico P et al. EASL 2011, Poster 731. |
| |
| 12. |
Lampertico P et al. AASLD 2010, Poster 391. |
| |
| 13. |
Snow-Lampart A et al. No resistance to tenofovir disoproxil fumarate detected after up to 144 weeks of therapy in patients monoinfected with chronic hepatitis B virus. Hepatology.2011;53(3):763-73. |
| |
| 14. |
Suzuki F et al. Selection of a virus strain resistant to entecavir in a nucleoside-naïve patient with hepatitis B of genotype H. J Clin Virol. 2007;39(2):149-52. |
| |
| 15. |
Guo JJ et al. Dynamics of hepatitis B virus resistance to entecavir in a nucleoside/nucleotide-naïve patient. Antiviral Res. 2009;81(2):180-3. |
| |
| 16. |
Mirandola S et al. Large-scale survey of naturally occurring HBV polymerase mutations associated with anti-HBV drug resistance in untreated patients with chronic hepatitis B. J Viral Hepat. 2011;18(7):e212-6. |
| |
| 17. |
Berg T et al. Tenofovir is effective alone or with emtricitabine in adefovir-treated patients with chronic-hepatitis B virus infection. Gastroenterology. 2010;139(4):1207-17. |
| |
| 18. |
Dakin H et al. Mixed treatment comparison meta-analysis evaluating the relative efficacy of nucleos(t)ides for treatment of nucleos(t)ide-naive patients with chronic hepatitis B. Value Health. 2010;13(8):934-45. |
| |
| 19. |
Colombo GL et al. A cost-effectiveness analysis of different therapies in patients with chronic hepatitis N in Italy. ClinicoEconomics and Outcomes Research. 2011;3:1-10. |
